Letters Bisphosphonates and cancer

More data using same database

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5315 (Published 29 September 2010) Cite this as: BMJ 2010;341:c5315
  1. Ellen Wright, clinical academic fellow1,
  2. Paul T Seed, senior lecturer in medical statistics2,
  3. Peter Schofield, research fellow1,
  4. Roger Jones, emeritus professor of general practice1
  1. 1Department of Primary Care and Public Health Sciences, King’s College London, Capital House, London SE1 3QD, UK
  2. 2King’s College London, Divisions of Reproduction and Endocrinology and Health and Social Care Research, St Thomas’ Hospital, London SE1 7EH
  1. ellen.wright{at}kcl.ac.uk

    Green and colleagues report the risk of various gastrointestinal cancers with oral bisphosphonates.1 Using a similar dataset from the same database, we independently compared bisphosphonate prescribing in cases of upper gastrointestinal cancer with that in controls from 1995 (when alendronate was first licensed) to 2007.

    The odds of being a case increased 1.17 times for those taking bisphosphonates (odds …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe